{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:28:26Z","timestamp":1790011706478,"version":"4.0.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"NHMRC Fellowship"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drug and Alcohol Dependence"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1016\/j.drugalcdep.2012.12.009","type":"journal-article","created":{"date-parts":[[2013,1,12]],"date-time":"2013-01-12T05:31:35Z","timestamp":1357968695000},"page":"119-126","source":"Crossref","is-referenced-by-count":37,"title":["A randomised controlled trial of sublingual buprenorphine\u2013naloxone film versus tablets in the management of opioid dependence"],"prefix":"10.1016","volume":"131","author":[{"given":"N.","family":"Lintzeris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.Y.","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.J.","family":"Dunlop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Larance","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.R.","family":"Rivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.M.","family":"Holland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Degenhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Muhleisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Hurley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drugalcdep.2012.12.009_bib0005","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1136\/bmj.302.6791.1481","article-title":"Randomisation","volume":"302","author":"Altman","year":"1991","journal-title":"BMJ"},{"key":"10.1016\/j.drugalcdep.2012.12.009_bib0010","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1037\/1064-1297.2.3.244","article-title":"Comparative epidemiology of dependence on tobacco, alcohol, controlled substances, and inhalants: basic findings From the National Comorbidity Survey","volume":"2","author":"Anthony","year":"1994","journal-title":"Exp. Clin. Psychopharmacol."},{"key":"10.1016\/j.drugalcdep.2012.12.009_bib0015","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1111\/j.1360-0443.2007.01979.x","article-title":"A randomized trial of effectiveness and cost-effectiveness of observed versus unobserved administration of buprenorphine\u2013naloxone for heroin dependence","volume":"102","author":"Bell","year":"2007","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2012.12.009_bib0020","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1136\/bjo.86.8.940","article-title":"Presumed ocular candidiasis in drug misusers after intravenous use of oral high dose buprenorphine (Subutex)","volume":"86","author":"Cassoux","year":"2002","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.drugalcdep.2012.12.009_bib0025","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1360-0443.2009.02843.x","article-title":"Abuse liability of intravenous buprenorphine\/naloxone and buprenorphine alone in buprenorphine-maintained intravenous heroin abusers","volume":"105","author":"Comer","year":"2010","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2012.12.009_bib0030","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1080\/10717540490280688","article-title":"Development of mucoadhesive dosage forms of buprenorphine for sublingual drug delivery","volume":"11","author":"Das","year":"2004","journal-title":"Drug Deliv."},{"key":"10.1016\/j.drugalcdep.2012.12.009_bib0035","doi-asserted-by":"crossref","first-page":"161","DOI":"10.5694\/j.1326-5377.2009.tb02729.x","article-title":"Injection of medications used in opioid substitution treatment in Australia after the introduction of a mixed partial agonist\u2013antagonist formulation","volume":"191","author":"Degenhardt","year":"2009","journal-title":"Med. J. Aust."},{"key":"10.1016\/j.drugalcdep.2012.12.009_bib0040","series-title":"Estimating the Number of Current Regular Heroin Users in NSW and Australia 1997\u20132002","author":"Degenhardt","year":"2004"},{"key":"10.1016\/j.drugalcdep.2012.12.009_bib0045","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0376-8716(03)00169-8","article-title":"Buprenorphine versus methadone maintenance: a cost-effectiveness analysis","volume":"71","author":"Doran","year":"2003","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2012.12.009_bib0050","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1080\/0959523031000154508","article-title":"Groin tissue necrosis requiring skin graft following parenteral abuse of buprenorphine tablets","volume":"22","author":"Feeney","year":"2003","journal-title":"Drug Alcohol Rev."},{"key":"10.1016\/j.drugalcdep.2012.12.009_bib0055","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1111\/j.1365-2125.2010.03759.x","article-title":"(R)- and (S)-methadone and buprenorphine concentration ratios in maternal and umbilical cord plasma following chronic maintenance dosing in pregnancy","volume":"70","author":"Gordon","year":"2010","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.drugalcdep.2012.12.009_bib0060","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3109\/00952998709001515","article-title":"Two new rating scales for opiate withdrawal","volume":"13","author":"Handelsman","year":"1987","journal-title":"Am. J. Drug Alcohol Abuse"},{"key":"10.1016\/j.drugalcdep.2012.12.009_bib0065","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1360-0443.2004.00958.x","article-title":"Buprenorphine diversion and injection in Melbourne, Australia: an emerging issue?","volume":"100","author":"Jenkinson","year":"2005","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2012.12.009_bib0070","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1080\/00498250701251126","article-title":"Comparison of cerebral pharmacokinetics of buprenorphine and norbuprenorphine in an in vivo sheep model","volume":"37","author":"Jensen","year":"2007","journal-title":"Xenobiotica"},{"key":"10.1016\/j.drugalcdep.2012.12.009_bib0075","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1017\/S0033291702006074","article-title":"Short screening scales to monitor population prevalences and trends in non-specific psychological distress","volume":"32","author":"Kessler","year":"2002","journal-title":"Psychol. Med."},{"key":"10.1016\/j.drugalcdep.2012.12.009_bib0080","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1046\/j.1360-0443.1998.93454910.x","article-title":"Relationship of plasma buprenorphine and norbuprenorphine to withdrawal symptoms during dose induction, maintenance and withdrawal from sublingual buprenorphine","volume":"93","author":"Kuhlman","year":"1998","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2012.12.009_bib0085","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.drugalcdep.2011.04.002","article-title":"Post-marketing surveillance of buprenorphine-naloxone in Australia: diversion, injection and adherence with supervised dosing","volume":"118","author":"Larance","year":"2011","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2012.12.009_bib0090","series-title":"National Clinical Guidelines and Procedures for the Use of Buprenorphine in the Treatment of Opioid Dependence","author":"Lintzeris","year":"2006"},{"key":"10.1016\/j.drugalcdep.2012.12.009_bib0095","doi-asserted-by":"crossref","first-page":"575","DOI":"10.47102\/annals-acadmedsg.V34N9p575","article-title":"Severe upper limb complications from parenteral abuse of Subutex","volume":"34","author":"Loo","year":"2005","journal-title":"Ann. Acad. Med. Singapore"},{"key":"10.1016\/j.drugalcdep.2012.12.009_bib0100","first-page":"158","article-title":"Crushing sublingual buprenorphine naloxone tablets: impact upon dissolution time for supervised dispensing","volume":"29","author":"Muhleisen","year":"2010","journal-title":"Aust. Pharm."},{"key":"10.1016\/j.drugalcdep.2012.12.009_bib0105","series-title":"Suboxone Sublingual Film \u2013 Approved Product Information","author":"Reckitt Benckiser (Australia) Pty Ltd.","year":"2011"},{"key":"10.1016\/j.drugalcdep.2012.12.009_bib0110","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1001\/jama.285.15.2006","article-title":"CONSORT revised \u2013 improving the reporting of randomized trials","volume":"285","author":"Rennie","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.drugalcdep.2012.12.009_bib0115","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1023\/A:1013867826835","article-title":"The WHO quality of life assessment instrument (WHOQOL-Bref): the importance of its items for cross-cultural research","volume":"10","author":"Saxena","year":"2001","journal-title":"Qual. Life Res."},{"key":"10.1016\/j.drugalcdep.2012.12.009_bib0120","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1001\/jama.1994.03520020051014","article-title":"Assessing the quality of randomization from reports of controlled trials published in obstetrics and gynecology journals","volume":"272","author":"Schulz","year":"1994","journal-title":"JAMA"},{"key":"10.1016\/j.drugalcdep.2012.12.009_bib0125","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1159\/000279766","article-title":"Bioavailability of buprenorphine from crushed and whole buprenorphine (Subutex) tablets","volume":"16","author":"Simojoki","year":"2010","journal-title":"Eur. Addict. Res."},{"key":"10.1016\/j.drugalcdep.2012.12.009_bib0130","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/clpt.2010.352","article-title":"Induction of opioid-dependent individuals onto buprenorphine and buprenorphine\/naloxone soluble-films","volume":"89","author":"Strain","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.drugalcdep.2012.12.009_bib0135","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.drugpo.2007.03.002","article-title":"Prevalence of diversion and injection of methadone and buprenorphine among clients receiving opioid treatment at community pharmacies in New South Wales, Australia","volume":"19","author":"Winstock","year":"2008","journal-title":"Int. J. Drug Policy"},{"key":"10.1016\/j.drugalcdep.2012.12.009_bib0140","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1080\/10550880903028841","article-title":"What is diversion of supervised buprenorphine and how common is it?","volume":"28","author":"Winstock","year":"2009","journal-title":"J. Addict. Dis."},{"key":"10.1016\/j.drugalcdep.2012.12.009_bib0145","series-title":"Guidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid Dependence","author":"World Health Organisation","year":"2009"}],"container-title":["Drug and Alcohol Dependence"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871612004851?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871612004851?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T16:57:29Z","timestamp":1745945849000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0376871612004851"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":29,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["S0376871612004851"],"URL":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2012.12.009","relation":{},"ISSN":["0376-8716"],"issn-type":[{"value":"0376-8716","type":"print"}],"subject":[],"published":{"date-parts":[[2013,7]]}}}